
Lexicon Pharmaceuticals upgraded to Buy with key drug trial results and NDA plans ahead.
Lexicon Pharmaceuticals has been upgraded to a Buy rating due to several upcoming catalysts in its drug pipeline. The company plans to resubmit its New Drug Application (NDA) for ZYNQUISTA in treating Type 1 Diabetes by Q4 2026, pending safety data f...





